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ABSTRACT 
Fish oils containing omega-3 fatty acids (OM3FA) are widely prescribed in the management of dyslipidemia. An asso-
ciation between OM3FA and reduced risk of atrial fibrillation (AF) has been proposed. We examined the impact of 
OM3FA exposure on the risk of developing AF in patients with cardiovascular disease. Data was obtained from elec-
tronic medical records of patients seen by our cardiology service between 2005 and 2007. Patients were excluded if AF 
developed prior to, or on the day of, OM3FA exposure. A total of 11,360 subjects were eligible for analyses. Subjects 
exposed to OM3FA were at higher risk for AF. Nearly all AF risk factors were significantly more prevalent in the 
OM3FA exposed group. As expected, those prescribed OM3FA were also more likely to be prescribed statins, ACE in-
hibitors, aspirin, and beta blockers. AF occurred in 8.5% (221/2600) of OM3FA exposed subjects and 23.5% 
(2054/8760) of those not exposed. After controlling for AF risk factors, OM3FA exposed subjects were 74% less likely 
to develop AF than those not exposed to OM3FA (odds ratio 0.26, 95%CI 0.22-0.30, p < 0.0001). After controlling for 
risk factors for AF, OM3FA use is significantly associated with a reduced risk for AF in patients with cardiovascular 
disease. Potential mechanisms which may explain the ability of OM3FAs to reduce AF include its anti-inflammatory 
and anti-arrhythmic properties. The optimal dose of OM3FA to prevent AF is unknown and warrants prospective as-
sessment in a randomized controlled trial of OM3FAs powered to detect significant differences in AF. 
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1. Introduction 
Atrial fibrillation (AF) is common in the hospital setting 
and the most prevalent sustained heart arrhythmia in 
clinical practice [1]. Patients with cardiovascular disease, 
such as coronary artery disease, congestive heart failure, 
cardiac valve disease, hypertension and increased size of 
the left atrium have higher occurrence of atrial fibrilla-
tion. Heart failure patients who develop atrial fibrillation 
are admitted to the hospital more often and have longer 
hospital stays [2]. The aging population will further con-
tribute to a higher prevalence of atrial fibrillation result-
ing in more hospital admissions and increased health care 
costs.  
Omega-3 fatty acids (OM3FA) have been shown to 
significantly reduce the risk of cardiac arrhythmias, in-
cluding atrial fibrillation and all-cause mortality in pa-
tients with known cardiovascular disease (CVD) [3-6]. 
OM3FA are a class of essential n-3 polyunsaturated fatty 
acids (n-3 PUFA) that influence cardiac myocytes at the 
cellular level contributing to an antiarrhythmic benefit of 
fish oil [7]. The antiarrhythmic properties of fish oil may 
help to reduce the incidence of outpatient and inpatient 
development of atrial fibrillation. 
The objective of this study was to examine the impact 
of OM3FA exposure on the subsequent risk of develop-
ing atrial fibrillation (AF) in patients with cardiovascular 
disease. 
2. Methods 
This was a retrospective, observational, cohort study 
conducted at an academic medical center in Kansas City. 
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The study was approved by the institutional review board. 
Data were obtained from electronic medical records 
(EMR) of patients seen by the cardiology service between 
2005 and 2007. AF was defined from EMR ICD coding. 
Patients were excluded if AF developed prior to, or on the 
day of, OM3FA exposure. Patients with incomplete car-
diac echocardiographic data or other important medical 
information were also excluded. Patient demographics, 
dates of OM3FA exposure or AF development, drug 
therapy, and risk factors that influence AF development 
were obtained. AF risk factors were identified via an ex-
tensive literature review. A consensus list among the in-
vestigators was developed based upon the strength of the 
data and availability of the variables. The final list of AF 
risk factor variables is provided in Table 1.  
Using SAS (version 9.1.4) and an a priori alpha level 
of 0.05 to indicate statistical significance, univariate 
analyses (chi square and t-tests) and unconditional, mul-
tivariable, logistic regression were performed. A stepwise 
selection model with entry and retention set at 0.15 and  
 
Table 1. Baseline demographics and risk factors for atrial 
fibrillation in subjects exposed (+OM3FA) or not exposed (- 
OM3FA) to omega 3 fatty acids. 
 -OM3FA 
Exposure 
(n = 8760) 
+OM3FA 
Exposure 
(n = 2600) 
P-value 
Demographics: 
Age, mean years (SD) 63.2 (16.4) 66.0 (11.9) <0.0001*
<19, n (%) 63 (0.7) 0 (0) 
20-29, n (%) 262 (3) 10 (0.4) 
30-45, n (%) 941 (10.7) 116 (4.5) 
46-59, n (%) 2183 (24.9) 636 (24.5) 
>59, n (%) 5311 (60.6) 1838 (70.7) 
<0.0001 
Race† 
Asian, n (%) 23 (0.8) 6 (0.6) 
African American , n (%) 502 (17.5) 81 (8.0) 
Hispanic, n (%) 85 (3.0) 17 (1.7) 
Caucasian, n (%) 2267 (78.8) 903 (89.7) 
<0.0001 
Male gender, n (%) 4580 (52.3) 1694 (65.2) <0.0001 
Risk Factors for AF    
Coronary heart disease, n (%) 2511 (28.7) 1480 (56.9) <0.0001 
Hypertension, n (%) 4583 (52.3) 1515 (58.2) <0.0001 
Valvular heart disease, n (%) 1909 (21.8) 513 (19.7) 0.0242 
Diabetes, n (%) 1637 (18.7) 584 (22.5) <0.0001 
Heart failure, n (%) 2040 (23.3) 733 (28.2) <0.0001 
Abnormal left atrial size (>4 
cm), n (%) 
6591 (75.2) 2101 (80.8) <0.0001 
Left ventricular ejection 
fraction, mean % (SD) 
54 (12) 52 (12) <0.0001 
Drug use: 
Statins, n (%) 4754 (54.3) 2197 (84.5) <0.0001 
ACE inhibitors, n (%) 4533 (51.8) 1734 (66.7) <0.0001 
Aspirin, n (%)  5704 (65.1) 2277 (87.6) <0.0001 
‡ Beta-blockers, n (%) 5471 (62.5) 1955 (75.2) <0.0001 
AF development, n (%) 2054 (23.5)  221 (8.5)  <0.0001 
* Satterthwaite correction used for unequal variances. † Excluded 
from analyses due to missing data (n = 1007 + OM3FA, 2877 – 
OM3FA exposure). ‡ Excluded from model entry due to significant 
association between use and AF development, presumably from 
the use of beta blockade for AF rate control. First date of exposure 
to beta blockers was unknown. 
0.05, respectively, was used to determine the probability 
of developing AF after exposure to OM3FA, while con-
trolling for AF risk factors. Successful model conver-
gence was noted during the stepwise selection procedure. 
Interactions between model variables were assessed by 
incorporating the product of the various explanatory fac-
tors and assessing their impact on the model.  
No statistically significant interactions existed between 
the explanatory variables. Goodness of fit for the model 
was assessed by evaluating the Hosmer and Lemeshow 
test which indicated the predicted responses generated by 
our model were not statistically different from those 
which we observed. Model overfitting was checked by 
determining if each explanatory variable included in the 
model had at least 10 positive outcomes. Odds ratios and 
their corresponding 95% confidence intervals were cal-
culated for the explanatory variables by exponentiation 
of the values of the regression coefficients. 
3. Results 
A total of 11,360 subjects were eligible for analyses. 
Demographic data for the study population are summa-
rized in Table 1. Subjects exposed to OM3FA were at 
higher risk for AF. Nearly all AF risk factors (such as 
age, coronary heart disease, hypertension, diabetes, heart 
failure, and abnormal left atrial size) were significantly 
more prevalent (all p’s < 0001) in the OM3FA exposed 
group. Left ventricular ejection fraction was significantly 
lower in patients given OM3FA). As expected, those 
prescribed OM3FA were also more likely to be pre-
scribed statins, angiotensin converting enzyme inhibitors, 
aspirin, and beta blockers due to their higher risk profile 
and medical indications. 
AF occurred in 8.5% (221/2600) of OM3FA exposed 
subjects and 23.5% (2054/8760) of those not exposed (p 
< 0001). After controlling for AF risk factors, OM3FA 
exposed subjects were 74% less likely to develop AF 
than those not exposed to OM3FA (odds ratio 0.26, 
95%CI 0.22-0.30, p < 0.0001). The final model included 
the variables provided in Table 2. Therefore, in spite of 
being at significantly greater risk of AF due to a much 
higher predisposing factor profile, those patients on 
OM3FA had a significantly reduced actual occurance of 
AF, suggesting a possible protective effect of these 
substances. 
4. Discussion 
The impact of OM3FA on patient outcomes was exam-
ined in the GISSI-Preventive Trial, a prospective ran-
domized controlled trial of 11,324 patients with known 
CVD who were randomized to receive either 300 mg of 
Vitamin E, 850 mg of OM3FA, both or neither. This 
study reported a statistically significant reduction of all  
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Table 2. Unconditional, multivariable, logistic regression, modeling the probability of developing atrial fibrillation after ex-
posure to omega 3 fatty acids (OM3FA). 
Parameter ML Estimate Odd Ratio 95% CI p value 
Intercept –2.8849 n/a n/a <0.0001 
OM3FA use –1.3096 0.270 0.232-0.314 <0.0001 
Statin use –0.2694 0.764 0.687-0.849 <0.0001 
Age groups (in years) 
<19 vs. 30-45 –0.4373 1.156 0.732-1.825 0.4703 
20-29 vs. 30-45 0.1446 0.646 0.197-2.116 0.5350 
46-59 vs. 30-45 0.4099 1.507 1.184-1.917 0.0009 
>59 vs. 30-45 1.2448 3.472 2.779-4.338 <0.0001 
Male Gender 0.1580 1.171 1.060-1.294 0.0019 
History of valvular heart disease 0.5634 1.757 1.575-1.959 <0.0001 
History of diabetes –0.1608 0.851 0.751-0.965 0.0121 
Abnormal left atrial size ‡ 0.8092 1.330 1.192-1.484 <0.0001 
‡ Abnormal left atrial size defined as >4 cm. ML, maximum likelihood; n/a = not applicable; OM3FA, omega 3 fatty acids. 
 
cause mortality related to cardiac death in patients taking 
OM3FA [4], however no emphasis was made on the ef-
fects of OM3FA on cardiac arrhythmias. Fish oil sup-
plementation has been reported to reduce the incidence of 
postoperative AF markedly from 33 to 15% [3] and one 
year reduction in the incidence of atrial fibrillation from 
15.4 to 1.9% in patients following myocardial infarction 
[5,6]. It has been hypothesized that higher levels of cir-
culating n-3 PUFA (polyunsaturated fatty acids) of which 
OM3FA are an essential class may reduce cardiac myo-
cyte membrane excitability and reduce cardiac arrhyth-
mias whereas lower levels of circulating n-3 PUFA may 
promote cardiac myocyte membrane excitability leading 
to increased cardiac arrythmias [7]. 
Similarly, a 79% reduction in the incidence of AF was 
reported in dogs treated with oral n-3 PUFA who under-
went vagally induced AF [8]. The proposed mechanism 
was a reduction of atrial conduction velocity [9]. Struc-
tural remodeling pertaining to changes in extracellular 
matrix and gap junction connexins have shown that N-3 
PUFA treated dogs had 60% and 42% reduced connexin 
proteins CX40 and CX43, respectively [8]. Hypotheti-
cally, with reduction in gap junctions amongst cardiac 
cells, the capacitance to create an effective action poten-
tial is diminished, thus leading to prevention of aberrant 
arrhythmias. However, these results come from an acute 
14 day treatment course and long term benefits cannot be 
deduced. The EURAMIC study proposes that acute 
PUFA exposure prevented atrial fibrosis and conduction 
abnormalities which may explain AF suppression [10]. 
EPA and DHA, which are present in fish oil have also 
been shown to reduce resting heart rate and increase left 
ventricular filling capacity [11] due to the ability of 
OM3FA to increase electrical stability of the myocar-
dium by inhibiting calcium channels and the sodium/ 
hydrogen exchanger and thus mediating its antiarrhyth-
mic effect [12]. 
Many animal models have supported favorable out-
comes on cardiac function imposed by long chain n-3 
fatty acids in fatty fish. Rat models have shown reduction 
in peripheral vascular resistance [13], reduced left ven-
tricular hypertrophy in hypertensive animals [14], de-
creased myocardial oxygen consumption with reduction 
of serum markers, improved contractile recovery, and 
reperfusion post ischemia [15]. With multivariate analy-
sis in humans, consumption of tuna or other broiled or 
baked fish was associated with a lower heart rate, lower 
systemic vascular resistance, greater stroke volume [16], 
slower atrioventricular conduction (longer PR interval), 
and lower likelihood of abnormal ventricular repolariza-
tion (prolonged QT) [17] with added benefit in serum 
triglycerides (–27 mg/dL) and HDL (+1.6 mg/dL) 
[18,19]. These clinical correlations ultimately exert a 
combined effort for lowering the incidence of atrial fib-
rillation [1] and possibly other less common cardiac ar-
rhythmias. On the contrary, fried fish intake was associ-
ated with left ventricular (LV) wall motion abnormalities, 
reduced ejection fraction, reduced cardiac output, and 
higher mean BP and SVR [16]. 
As with all retrospective study designs, our study has 
important limitations which must be noted. We were un-
able to definitively conclude that all significant risk fac-
tors for AF were controlled for in the regression model. 
There is also a concordance of high Caucasian preva-
lence in our study which limits benefit for multi-ethnic 
analysis. Additionally, some therapies which are used to 
treat AF are also effective in its prevention (e.g. beta 
blockade), which complicates analyses and interpretation. 
We therefore excluded beta blocker use from model en-
try due to the significant association between the devel-
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opment of AF and beta blocker use for ventricular rate 
control. Had we been able to determine the first date of 
exposure to beta blockers we would have been able to 
differentiate between beta blockade for rate control ver-
sus non-AF related pharmacotherapy.  
The optimal dose of OM3FA to prevent AF is un-
known and warrants prospective assessment in a ran-
domized controlled trial of omega-3 fatty acids powered 
to detect significant differences in AF. Doses which are 
typically recommended for cardioprotection (e.g. 1.5 
grams daily) are usually well tolerated with minimal ad-
verse effects and interactions with other cardiovascular 
medications [20]. There may be a dose dependant effect of 
OM3FA in order to reach serum concentrations high 
enough to contribute to cardiac myocyte membrane sta-
bilization and subsequently lower incidence of arrhyth-
mias Overall it appears that the potential benefits of 
consumption of fish oils from fatty fish outweigh risks and 
that there are many potential roles in the symptomatic, 
physiologic, and pathologic reduction of cardiovascular 
disease [21]. 
5. Summary 
After controlling for risk factors for AF, the use of 
omega-3 fatty acid was significantly associated with a 
reduced risk (74%) for AF in a patient cohort with car-
diovascular disease. Further clinical trials are needed to 
confirm this finding, but this study supports prior inves-
tigations suggesting that dietary augmentation of OM3- 
FA in the population with cardiovascular diseases. 
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